# Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

> **NCT02315196** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 62 (actual)

## Conditions studied

- Estrogen Receptor-negative Breast Cancer
- HER2-negative Breast Cancer
- Progesterone Receptor-negative Breast Cancer
- Stage IIA Breast Cancer
- Stage IIB Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Triple-negative Breast Cancer

## Interventions

- **DRUG:** pegylated liposomal doxorubicin hydrochloride
- **DRUG:** epirubicin hydrochloride
- **DRUG:** carboplatin
- **PROCEDURE:** therapeutic conventional surgery
- **DRUG:** paclitaxel
- **OTHER:** laboratory biomarker analysis
- **OTHER:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT02315196
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-02-25
- **Primary completion:** 2021-02-08
- **Final completion:** 2041-07
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2023-03-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02315196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02315196, "Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02315196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*